Evidence map›Paper›PMID 39253930›Full record

ReviewCurrent cancer drug targets2025

Targeting the Tumor Epigenetic Regulator SETDB1 for Tumor Therapy.

Cheng Peng, Nini Zhou, Tengjiang Chen, Jie Lei, Changwen Chen, Shunqin Zhu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cancer drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Cheng PengSchool of life Sciences, Southwest University, No.2 Tiansheng Road., Beibei, Chongqing, China.
Nini ZhouSchool of life Sciences, Southwest University, No.2 Tiansheng Road., Beibei, Chongqing, China.
Tengjiang ChenSchool of life Sciences, Southwest University, No.2 Tiansheng Road., Beibei, Chongqing, China.
Jie LeiSchool of life Sciences, Southwest University, No.2 Tiansheng Road., Beibei, Chongqing, China.
Changwen ChenSchool of life Sciences, Southwest University, No.2 Tiansheng Road., Beibei, Chongqing, China.
Shunqin ZhuSchool of life Sciences, Southwest University, No.2 Tiansheng Road., Beibei, Chongqing, China.

Funding

Science Foundation of School of Life Sciences SWU 20232005487601
6 · The paper itself

Abstract

Epigenetic alterations are implicated in the early stages of tumorigenesis and are widely recognized as a ubiquitous phenomenon in cancer development. Aberrant epigenetic modifications can alter the expression of target genes, induce heterochromatin formation, and gradually drive normal cells towards immortalized tumor cells with significant consequences. SETDB1 (SET domain bifurcated histone lysine methyltransferase 1), a typical histone methyltransferase, promotes the formation of heterochromatin and inhibits the transcription of genes by modifying the methylation of lysine 9 of histone 3. SETDB1 is usually highly expressed in tumors with high copy numbers, accompanied by poor prognosis and low patient survival rates, which is a typical case of abnormal epigenetic modification. We discuss the mechanism of SETDB1 in a variety of cancers and review the epigenetic inhibitors that have been reported in recent years, along with their anti-tumor effects. In addition, we summarize the role of SETDB1 in a variety of diseases and cell functions.

Indexed as

Antineoplastic AgentsEpigenesis, GeneticHistone-Lysine N-MethyltransferaseNeoplasmsAnimalsGene Expression Regulation, NeoplasticHumansMolecular Targeted TherapyAntineoplastic AgentsHistone-Lysine N-MethyltransferaseSETDB1 protein, humancancer progressionEpigenetic modificationhistone methyltransferase SETDB1inhibitorsignal pathwaystumor therapy.

Identifiers

PMID39253930

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.